Dolofast (Ketoprofen) is commonly used across therapeutic domains involving physical discomfort and inflammation. It is applied in contexts where supportive symptom management is appropriate, contributing to easing the overall symptom load.

This medication is relevant for easing symptoms related to inflammatory or irritative states and is commonly used to help with conditions characterized by periods of heightened symptoms. It is applied across therapeutic domains where additional symptomatic support is needed for relief from symptomatic management of joint pain, swelling, and stiffness associated with Rheumatoid Arthritis and Osteoarthritis; relief from discomfort following musculoskeletal injuries (sprains, strains), pain after dental procedures, primary dysmenorrhea (menstrual cramps), and gout flares; and addressing elevated fever (systemic temperature elevation).

“It is commonly used across conditions presenting with acute episodes, where managing symptom intensity is relevant for stability.”

By addressing these symptom clusters, Dolofast assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for Inflammation and Pain
Dolofast is commonly used for managing symptoms that create noticeable physiological strain, primarily by easing the burden of pain, swelling, and fever in conditions involving heightened physiological activity.

Regulatory References

1. NIH MedlinePlus Drug Information

The official eligibility profile for Dolofast (Ketoprofen) is defined by regulatory documents, establishing clear patient groups who must not use the medicine (contraindications) and populations that require restricted use.

Contraindicated Populations (Must Not Use)

Contraindication	Basis
Allergy/Sensitivity	Known hypersensitivity to Ketoprofen, aspirin, other NSAIDs, or a history of aspirin-induced asthma.
GI Disease	Active or recurrent history of gastrointestinal bleeding, peptic ulcers, or perforation.
Organ Failure	Severe renal or hepatic insufficiency, or severe, uncontrolled heart failure.
Surgery	Treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy	Patients in the third trimester of pregnancy (after 30 weeks gestation).

Restricted and Age-Related Use

• Pediatric Patients: Safety and effectiveness are not established by regulatory authorities for the full pediatric population (e.g., generally under 18 years for prescription forms), leading to a not recommended status for children.
• Elderly Patients: Use requires caution and close monitoring due to a heightened risk of serious gastrointestinal and kidney adverse events, necessitating careful management.
• Pregnancy/Lactation: Use is not recommended during the first two trimesters unless clearly necessary. It is also not recommended while breastfeeding due to insufficient data on excretion into human milk and potential infant risk.

The official regulatory profile for Diclofenac, the active component often associated with products such as Dolofast, identifies several clinically significant interactions requiring caution and monitoring.

Contraindicated and High-Risk Combinations

• Other NSAIDs and Aspirin: Concomitant use with other systemic non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective inhibitors, is restricted. Co-administration with aspirin is also generally not recommended due to a documented increase in the risk of serious gastrointestinal events, such as bleeding and ulceration.
• Anticoagulants and Anti-platelet Agents: Combining with agents like warfarin, as well as selective serotonin reuptake inhibitors (SSRIs) and corticosteroids, increases the pharmacodynamic risk of hemorrhage.

Exposure and Therapeutic Modification

• Lithium and Digoxin: Official labeling indicates that this drug may raise the plasma concentrations of co-administered Lithium and Digoxin, necessitating close monitoring of serum levels to prevent toxicity.
• Diuretics and Antihypertensives: The drug may reduce the efficacy of Diuretics and ACE Inhibitors due to inhibition of prostaglandin synthesis. The combination requires blood pressure and renal function monitoring due to an increased risk of nephrotoxicity, particularly in elderly or volume-depleted patients.
• CYP2C9 Inhibitors: As Diclofenac is primarily metabolized by the CYP2C9 enzyme, co-administration with strong CYP2C9 inhibitors (e.g., Voriconazole) significantly increases the systemic exposure (Cmax and AUC) of Diclofenac. A dosage adjustment may be warranted when administered with CYP2C9 inhibitors or inducers.

Targeted Inhibition of Prostaglandin Synthesis

Dolofast's mechanism is anchored in the reversible competitive inhibition of the Cyclooxygenase (COX) enzymes, particularly the COX-2 isoform, which initiates the production of prostaglandins from the arachidonic acid cascade. This targeted molecular suppression modifies early biochemical steps that influence physiological responses, resulting in a quantifiable decrease in the levels of key inflammatory mediators in affected tissues.

Dual Modulation of Peripheral and Central Signaling

The reduction of prostaglandins directly influences specific humoral and neural signaling pathways. In the periphery, the mechanism results in the attenuation of excessive mediator activity by decreasing the sensitization of nociceptive (pain) nerve endings. Centrally, the drug engages mechanisms that influence the hypothalamic temperature set point, leading to a dissipation of elevated core temperature.

Nonselective Action and Mechanistic Specificity

The mechanism involves nonselective inhibition of both COX-1 and COX-2. This action pattern means the therapeutic modulation of inducible COX-2 is functionally coupled with the concurrent inhibition of constitutive COX-1, which is responsible for homeostatic processes. The rate of pathway modulation is influenced by the rapid activity and absorption of the primary S(+)-enantiomer.

How to Use Dolofast: Official Administration Guidelines

The usage of Dolofast (Ketoprofen) follows specific guidelines which establish a framework for its administration, dosing, and duration. This medicine is approved for several routes, primarily oral (in both immediate-release and extended-release forms) as well as parenteral (injection) and topical applications, with availability varying by region.

---

Official Dosing Patterns

The established dosage regimens are differentiated by the intended use pattern and the form administered:

Usage Context	Typical Adult Dosing Range	Maximum Daily Limit
Chronic Conditions (IR Oral)	50 mg four times daily or 75 mg three times daily	300 mg
Chronic Conditions (ER Oral)	200 mg once daily	200 mg
Acute Pain (IR Oral)	25 mg to 50 mg every 6 to 8 hours as needed	300 mg

Extended-release forms are designated for long-term maintenance and are not recommended for the management of acute episodes.

---

Administration and Duration Constraints

To ensure proper administration, oral doses are typically taken with a full glass of water and may be consumed with food, milk, or an antacid to minimize potential gastrointestinal discomfort. Furthermore, extended-release formulations must be swallowed whole and should not be crushed or chewed, as this alters the designed delivery of the medicine.

Usage across all forms is guided by the principle of administering the lowest effective dose for the shortest possible duration consistent with treatment goals. Specific dose modifications are utilized for certain populations; for instance, a lower initial dose is generally considered for older or debilitated individuals, and maximum dose reductions are applied for patients with impaired renal or hepatic function.

Research Evidence / Overview of Studies

Summary of Research Scope

Clinical research has investigated the drug's use in moderate to severe arthritis. Studies evaluated the drug's use in participants with moderate to severe arthritis.

• Clinical Trials (Phase III): One key study examined outcomes related to joint function and pain reduction. The trial involved 500 participants over a 12-week period.
• Post-Market Surveillance: Observational research tracked outcomes in a larger patient group for up to two years. These studies explored long-term experiences in a larger patient group.

---

Findings on Outcomes

Inflammation and Pain

A meta-analysis suggested the presence of reduced inflammation over six months in groups that received the drug compared to the placebo groups. Findings regarding pain-related outcomes were mixed across different study designs.

• Some Phase II trials investigated changes in the reported need for rescue medication among participants.
• Other studies focused on the relationship between the drug's use and inflammatory biomarkers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

Joint Mobility and Function

Studies evaluated changes in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores in participants after three and six months of treatment. Research has explored the drug's role in a treatment regimen.

Combination with other Therapies

Research suggests that studies have explored the combination of the drug with physiotherapy. This research examined whether a combined approach influenced the reported frequency of flare-ups compared to drug use alone.

Studies compared the drug to traditional NSAIDs. The formulation of the drug was studied to assess its absorption profile. Long-term data extending beyond the two-year period studied are currently not available.

Key Studies & References

1. Efficacy and safety of paracetamol for pain relief: an overview of systematic reviews (Used for pain/inflammation outcomes and mixed findings)
2. Paracetamol Use in Patients With Osteoarthritis and Lower Back Pain: Infodemiology Study and Observational Analysis of Electronic Medical Record Data (Used for real-world usage data and combination therapy context)

Common questions about Dolofast (FAQ)

Q: What is the main purpose of Dolofast?

A: Dolofast (diclofenac potassium) is primarily indicated for the acute treatment of migraine attacks with or without aura in adults. It is not indicated for the prevention (prophylaxis) of migraines.

---

Q: How is Dolofast generally classified?

A: Dolofast is a medication that contains diclofenac potassium, which belongs to a class of medicines known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

---

Q: What is the key active ingredient in Dolofast?

A: The key active ingredient in Dolofast is diclofenac potassium, an NSAID derivative.

---

Q: Can Dolofast be used for long-term treatment of pain?

A: Use of the diclofenac potassium formulation in Dolofast is generally recommended only for short-term treatment. If prolonged use is being considered, monitoring the blood count may be suggested, as with other NSAIDs.

---

Q: Are there any known cardiac or circulatory risks associated with diclofenac, the active ingredient in Dolofast?

A: Clinical data suggests that the use of diclofenac, particularly at high amounts and over long periods, may be associated with a small potential for increased risk of arterial thrombotic events, such as myocardial infarction or stroke. For this reason, the shortest duration and lowest appropriate amount should be considered.

---

Q: Is Dolofast suitable for individuals with a history of asthma or allergies to other pain relievers?

A: Like other NSAIDs, Dolofast is generally not recommended for patients in whom attacks of asthma, hives (urticaria), or acute runny nose (rhinitis) have been brought on by aspirin (acetylsalicylic acid) or other NSAIDs.

---

Q: What is the general recommendation regarding using Dolofast with other NSAIDs?

A: The use of Dolofast alongside other NSAIDs, including those that target cyclooxygenase-2 (COX-2) specifically, should generally be avoided. This is due to the lack of research showing a combined benefit and the potential for a higher chance of undesirable effects.

Storage Requirements

Dolofast must be stored at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F). The product must be protected from both excessive heat and moisture and should not be stored in a bathroom. It is required to keep the medicine in its original container, ensuring the container remains tightly closed and is light-resistant.

Child-Safety and Disposal

For safety, the medicine must be stored out of the sight and reach of children, and safety caps must always be locked. For disposal, the preferred method is to use a formal drug take-back program. If a take-back option is unavailable, the alternative is to mix the product with an unappealing substance, place it in a sealed container, and discard it in the household trash, in accordance with local environmental regulations.